Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
132 USD | +0.15% | +6.74% | +21.03% |
Mar. 28 | Robert Davis, Merck CEO: Another obesity drug? | MT |
Mar. 28 | Merck: new indication approved for Keytruda in Europe | CF |
Evolution of the average Target Price on Merck & Co., Inc.
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering Merck & Co., Inc.
Truist Securities | |
Wells Fargo Securities | |
Societe Generale | |
UBS | |
Goldman Sachs | |
Barclays | |
Jefferies & Co. | |
Deutsche Bank Securities | |
BofA Securities | |
TD Cowen | |
Morgan Stanley | |
BMO Capital | |
HSBC | |
Atlantic Equities | |
Citigroup | |
Guggenheim | |
Berenberg Bank | |
Credit Suisse | |
JPMorgan Chase | |
Wolfe Research | |
SVB Securities LLC | |
Cantor Fitzgerald | |
Daiwa Securities | |
Cowen | |
SVB Leerink | |
Argus | |
RBC Capital Markets | |
RBC | Randall Stanicky |
JPMORGAN |
EPS Revisions
- Stock
- Equities
- Stock Merck & Co., Inc. - Nyse
- Consensus Merck & Co., Inc.